{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T20:10:39Z","timestamp":1760991039022,"version":"build-2065373602"},"reference-count":55,"publisher":"International Society of Global Health","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":" Background<\/jats:title> Respiratory syncytial virus (RSV) is a leading cause of severe acute lower respiratory infections in children. The World Health Organization recently recommended two passive RSV immunisation strategies for global use, but prices are yet to be determined in low- and middle-income countries (LMICs).<\/jats:p> <\/jats:sec> Methods<\/jats:title> We used a static cohort model to generate preliminary estimates of the potential health impact and cost-effectiveness of a maternal vaccine (RSVPreF, Abrysvo\u00ae, Pfizer) and a long-acting infant mAb (Nirsevimab, Beyfortus\u00ae, AstraZeneca, and Sanofi) over a 10-year period (2025\u20132034) in Mozambique. We incorporated cost-of-illness data from a recent study conducted in Maputo, Mozambique, and efficacy data from recent clinical trials. We compared each RSV prevention strategy to the current status quo (no pharmaceutical RSV prevention strategy). The primary outcome was the cost per disability-adjusted life year (DALY) averted from a government perspective, assuming year-round dose administration. We ran a range of deterministic scenarios, including a societal health perspective and a seasonal dose administration strategy. We also ran probabilistic uncertainty analyses and estimated the probability that each intervention would be cost-effective over a range of cost-effectiveness thresholds.<\/jats:p> <\/jats:sec> Results<\/jats:title> Year-round administration of a maternal vaccine (USD 5\/dose, 69% efficacy, 87% coverage, 6 months protection) could cost USD 80 million and prevent 4,671 RSV deaths. Year-round administration of the long-acting infant mAb (USD 5\/dose, 77% efficacy, 94% coverage, 5 months protection) could cost USD 85 million and prevent 5,128 RSV deaths. Over half the cost of the respective programs would be offset by healthcare cost savings. Compared to the current status quo, the cost per DALY averted from a government perspective was USD 288 (95% uncertainty interval 140\u2013574) for the maternal vaccine and USD 289 (95% uncertainty interval 160\u2013583) for the mAb. At an intervention price of USD 5 per dose, the probability is around 20% that either intervention is cost-effective at a threshold of 0.4 times the national GDP per capita.<\/jats:p> <\/jats:sec> Conclusions<\/jats:title> New passive immunisation interventions have the potential to prevent a substantial number of infant deaths in Mozambique. Both interventions have the potential to be cost-effective if priced below USD 5 per dose. A seasonal strategy could further improve cost-effectiveness if feasible to implement.<\/jats:p> <\/jats:sec>","DOI":"10.7189\/001c.137870","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:54:13Z","timestamp":1758128053000},"source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of respiratory syncytial virus prevention strategies in Mozambique: a modelling study"],"prefix":"10.7189","volume":"5","author":[{"given":"Esperan\u00e7a L","family":"Guimar\u00e3es","sequence":"first","affiliation":[{"name":"Instituto Nacional de Sa\u00fade, Marracuene district3943, Maputo, Mozambique"},{"name":"Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neele","family":"Rave","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assuc\u00eanio","family":"Chissaque","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Sa\u00fade, Marracuene district3943, Maputo, Mozambique"},{"name":"Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Rua da Junqueira 100, 1349-008 Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Braiton","family":"Maculuve","sequence":"additional","affiliation":[{"name":"Minist\u00e9rio da Sa\u00fade, Maputo, Mozambique"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuf\u00e1ria","family":"Muss\u00e1","sequence":"additional","affiliation":[{"name":"Universidade Eduardo Mondlane-Faculdade de Medicina, Maputo, Mozambique"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Palha","sequence":"additional","affiliation":[{"name":"Universidade Eduardo Mondlane-Faculdade de Medicina, Maputo, Mozambique"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farina L","family":"Shaaban","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis J.","family":"Bont","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clint","family":"Pecenka","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilsa","family":"de Deus","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Sa\u00fade, Marracuene district3943, Maputo, Mozambique"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"RSV GOLD III \u2013 Health Economics Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4223","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"author":"GAVI the Vaccine Alliance","key":"ref1","article-title":"Vaccine investment strategy"},{"article-title":"Inqu\u00e9rito Demogr\u00e1fico e de Sa\u00fade em Mo\u00e7ambique 2022\u201323. Relat\u00f3rio definitivo","year":"2024","author":"INE","key":"ref2"},{"article-title":"methods for the economic Evaluation of Health Care Programmes","year":"2015","author":"M. F. Drummond","key":"ref3"},{"author":"PAHO","key":"ref4","article-title":"ProVac Toolkit - PAHO\/WHO | Pan American Health Organization"},{"issue":"1","key":"ref5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12916-023-02827-5","article-title":"Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries","volume":"21","author":"S. Mahmud","year":"2023","journal-title":"BMC Med"},{"issue":"4","key":"ref6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jval.2022.11.014","article-title":"Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study","volume":"26","author":"X. Li","year":"2023","journal-title":"Value Health"},{"article-title":"WHO preferred product characteristics of monoclonal antibodies for passive immunization against respiratory syncytial virus (\u200eRSV)\u200e disease","year":"2021","author":"WHO","key":"ref7"},{"issue":"8","key":"ref8","first-page":"769","article-title":"Palivizumab for the prevention of respiratory syncytial virus infection","volume":"56","author":"A. L. Rogovik","year":"2010","journal-title":"Can Fam Physician"},{"year":"2003","key":"ref9","article-title":"Making choices in health: WHO guide to cost-effectiveness analysis"},{"issue":"12","key":"ref10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost\u2013effectiveness thresholds: pros and cons","volume":"94","author":"M. Y. Bertram","year":"2016","journal-title":"Bull World Health Organ"},{"article-title":"Respiratory Syncytial Virus (RSV) disease","year":"2023","author":"WHO","key":"ref11"},{"issue":"122","key":"ref12","first-page":"1","article-title":"Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data","author":"J. Ochalek","year":"2015","journal-title":"CHE Research Paper"},{"article-title":"GDP per capita (current US$) - Mozambique | Data","year":"2022","author":"World Bank","key":"ref13"},{"key":"ref14","article-title":"Immunization Data","author":"WHO","year":"2024","journal-title":"WHO Immunization Data portal - African Region - Current selection Mozambique"},{"issue":"Supplement_3","key":"ref15","doi-asserted-by":"publisher","first-page":"S218","DOI":"10.1093\/cid\/ciab509","article-title":"Deaths Attributed to Respiratory Syncytial Virus in Young Children in High\u2013Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance (CHAMPS)","volume":"73","author":"D. M. Blau","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ref16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12916-023-02853-3","article-title":"The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016","volume":"21","author":"J. Moyes","year":"2023","journal-title":"BMC Med"},{"issue":"2","key":"ref17","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2214-109X(21)00518-0","article-title":"Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project","volume":"10","author":"C. J. Gill","year":"2022","journal-title":"Lancet Glob Health"},{"article-title":"World Population Prospects - Population Division - United Nations","year":"2024","author":"UN","key":"ref18"},{"article-title":"Estimating the Economic Burden of Respiratory Syncytial Virus Infection among children under 2 years of age receiving care in Maputo, Mozambique","author":"N. Rave","key":"ref19","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.15.04076"},{"author":"A. Clark","key":"ref20","article-title":"Age distribution of respiratory syncytial virus disease in children <5 years of age in low-income and middle-income countries: a systematic review and meta-analysis"},{"article-title":"Mozambique: WHO and UNICEF estimates of immunization coverage: 2022 revision","year":"2023","author":"WUENIC","key":"ref21"},{"issue":"10340","key":"ref22","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Y. Li","year":"2022","journal-title":"The Lancet"},{"key":"ref23","article-title":"Vaccination and Immunization Statistics","author":"UNICEF","year":"2024","journal-title":"UNICEF DATA"},{"article-title":"Mo\u00e7ambique Inqu\u00e9rito Demogr\u00e1fico e de Sa\u00fade, 2011","year":"2011","author":"INE","key":"ref24"},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12916-023-02854-2","article-title":"The economic burden of RSV-associated illness in children aged < 5 years, South Africa 2011\u20132016","volume":"21","author":"J. Moyes","year":"2023","journal-title":"BMC Med"},{"issue":"4","key":"ref26","doi-asserted-by":"publisher","first-page":"e046563","DOI":"10.1136\/bmjopen-2020-046563","article-title":"Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model","volume":"11","author":"R. Baral","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"ref27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12916-023-02806-w","article-title":"Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa","volume":"21","author":"M. Koltai","year":"2023","journal-title":"BMC Med"},{"issue":"7","key":"ref28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S2213-2600(24)00184-X","article-title":"Respiratory syncytial virus vaccines: the future is bright","volume":"12","author":"Medicine TLR","year":"2024","journal-title":"Lancet Respir Med"},{"key":"ref29","article-title":"Mozambique\u2019s grand plan to reach more than 750,000 unimmunised children in 2024"},{"issue":"36","key":"ref30","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1016\/j.vaccine.2022.07.044","article-title":"Cost-effectiveness of rotavirus vaccination in Mozambique","volume":"40","author":"E. L. Guimar\u00e3es","year":"2022","journal-title":"Vaccine"},{"key":"ref31","article-title":"How will climate change impact Mozambique?","author":"F. Graham","year":"2023","journal-title":"Zitamar News"},{"key":"ref32","article-title":"Climate change could make RSV respiratory infection outbreaks less severe, more common","author":"M. Kelly","year":"2024","journal-title":"High Meadows Environmental Institute"},{"article-title":"Mozambique: Under-five mortality rate - Total","year":"2023","author":"UN IGME UI agency G for CME","key":"ref33"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1038\/s41467-019-13562-y","article-title":"Epidemic dynamics of respiratory syncytial virus in current and future climates","volume":"10","author":"R. E. Baker","year":"2019","journal-title":"Nat Commun"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.03.24302203v1","article-title":"Climatic drivers of seasonal dynamics for Respiratory Syncytial Virus (RSV) in Antananarivo, Madagascar, 2011-2021 | medRxiv","author":"T. H. Randriambolamanantsoa","journal-title":"Prepr Pap"},{"issue":"11","key":"ref36","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","article-title":"RSV Prefusion F Protein\u2013Based Maternal Vaccine \u2014 Preterm Birth and Other Outcomes","volume":"390","author":"I. Dieussaert","year":"2024","journal-title":"N Engl J Med"},{"article-title":"Influenza: NICD recommendations for the diagnosis, management, prevention and public health response","year":"2024","author":"NICD","key":"ref37"},{"key":"ref38","article-title":"Respiratory Syncytial Virus Infection (RSV)","author":"CDC","year":"2024","journal-title":"RSV Immunization Guidance for Infants and Young Children"},{"article-title":"Immunisation","year":"2024","author":"Health Protection Surveillance Centre","key":"ref39"},{"issue":"2","key":"ref40","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.vaccine.2020.11.028","article-title":"A cost-effectiveness analysis of South Africa\u2019s seasonal influenza vaccination programme","volume":"39","author":"I. Edoka","year":"2020","journal-title":"Vaccine"},{"issue":"12","key":"ref41","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1080\/13696998.2020.1836923","article-title":"Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK","volume":"23","author":"O. Narayan","year":"2020","journal-title":"J Med Econ"},{"article-title":"Agenda de Investiga\u00e7\u00e3o em Sa\u00fade (AGISA), 2024 - 2028","year":"2024","author":"MISAU","key":"ref42"},{"article-title":"GBD Results","year":"2021","author":"GBD. Institute for Health Metrics and Evaluation","key":"ref43"},{"key":"ref44","first-page":"1","article-title":"Risk factors and circulation pattern of respiratory syncytial virus in children under 2 years in Maputo, Mozambique","volume":"0","author":"M. Pale","year":"2024","journal-title":"Int Health"},{"article-title":"Global Burden of Disease Study 2019 (GBD 2019) Disability Weights","year":"2023","author":"GBD","key":"ref45"},{"key":"ref46","first-page":"391","article-title":"Challenges and opportunities for respiratory syncytial virus vaccines","volume":"372","author":"B. S. Graham","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"author":"UNICEF","key":"ref47","article-title":"Supply catalogue"},{"article-title":"Handling fees","year":"2024","author":"UNICEF","key":"ref48"},{"issue":"1","key":"ref49","doi-asserted-by":"publisher","first-page":"2040329","DOI":"10.1080\/21645515.2022.2040329","article-title":"Potential impact and cost-effectiveness of injectable next-generation rotavirus vaccines in 137 LMICs: a modelling study","volume":"18","author":"F. Debellut","year":"2024","journal-title":"Hum Vaccines Immunother"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/s12889-020-08595-8","article-title":"Cost of illness for childhood diarrhea in low- and middle-income countries: a systematic review of evidence and modelled estimates","volume":"20","author":"R. Baral","year":"2024","journal-title":"BMC Public Health"},{"issue":"10","key":"ref51","doi-asserted-by":"publisher","first-page":"E1611","DOI":"10.1016\/S2214-109X(24)00269-9","article-title":"Respiratory syncytial virus infection among children younger than 2 years admitted to a paediatric intensive care unit with extended severe acute respiratory infection in ten Gavi-eligible countries: the RSV GOLD\u2014ICU Network study","volume":"12","author":"D. N. Abdelrahman","year":"2024","journal-title":"The Lancet Global Health"},{"article-title":"RSV Vaccine and mAb Snapshot","year":"2023","author":"PATH","key":"ref52"},{"article-title":"Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 23-26 September 2024","year":"2024","author":"SAGE","key":"ref53"},{"issue":"16","key":"ref54","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"B. Kampmann","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"ref55","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMc2214773","article-title":"Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants","volume":"388","author":"W. J. Muller","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Journal of Global Health Economics and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/joghep.scholasticahq.com\/article\/137870-cost-effectiveness-of-respiratory-syncytial-virus-prevention-strategies-in-mozambique-a-modelling-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T19:46:25Z","timestamp":1760989585000},"score":1,"resource":{"primary":{"URL":"https:\/\/joghep.scholasticahq.com\/article\/137870-cost-effectiveness-of-respiratory-syncytial-virus-prevention-strategies-in-mozambique-a-modelling-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":55,"URL":"https:\/\/doi.org\/10.7189\/001c.137870","relation":{},"ISSN":["2806-6073"],"issn-type":[{"type":"electronic","value":"2806-6073"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}